About: Empirically driven definitions of "good," "moderate," and "poor" levels of functioning in the treatment of schizophrenia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Empirically driven definitions of "good," "moderate," and "poor" levels of functioning in the treatment of schizophrenia Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 14 December 2012

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2012 (ast) наукова стаття, опублікована в грудні 2012 (uk) scientific article published on 14 December 2012 (en) مقالة علمية نشرت في 14 ديسمبر 2012 (ar)
publication date	wds:Q37302364-97585D66-A057-47EE-8EAB-AEEE4D593D7B
publication date	2012-12-14 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37302364-E20A6C94-6671-4F13-8599-FBED82BA469B
language of work or name	English
exact match	wds:Q37302364-221DAB9D-751D-4BB7-8976-A9DDAB08924D
exact match	https://scigraph.springernature.com/pub.10.1007/s11136-012-0335-z
cites work	wds:Q37302364-02FA1072-CD02-4553-8793-D4BD4C2D5EE5 wds:Q37302364-1192AD3F-8967-4E64-A0C8-6D57A5EFED6E wds:Q37302364-162023F0-61DB-4737-9A2B-011CA3382873 wds:Q37302364-21109B0B-2824-4F0D-B605-123ACD4043D9 wds:Q37302364-21777398-B4B2-4552-A69D-71C2CAF929FD wds:Q37302364-246E20DA-30A8-4445-93AF-F9930053DB62 wds:Q37302364-34BF2A95-B307-4DB1-A9A7-0704A0052AF1 wds:Q37302364-43E18D88-EE81-4B5A-9918-9AE1A9EC665B wds:Q37302364-5B341EE1-B826-45BC-889D-EFEB035DC40E wds:Q37302364-5D79FD61-4996-4380-B3BA-CB6B8BBAFB4C wds:Q37302364-65F13A23-38A1-4CD2-AD41-C896BF69147F wds:Q37302364-7C3D45E3-BAB7-41F2-BC70-313AC7AAD186 wds:Q37302364-85FD421C-55CE-4CD0-9553-2FC121D44EDD wds:Q37302364-866D50C1-1A95-4131-A504-3A061A4E6014 wds:Q37302364-87EAD904-2A64-4334-94E8-34B6850C4CF8 wds:Q37302364-8BC29DD5-B7F0-455A-B64D-58B7AD108964 wds:Q37302364-99C13FF6-52E3-4D07-BDB3-CC249F54FA15 wds:Q37302364-99E44E2E-7659-46ED-907D-9890EA6B1FE1 wds:Q37302364-9BA7E26D-0A1F-4B09-9E33-E7D300138473 wds:Q37302364-9D663591-E328-4E93-9C70-CA3B5EE698BB wds:Q37302364-9F932103-B03F-4CD1-91A5-6586AB7D6883 wds:Q37302364-A9970EA7-BFC2-4642-A344-24AB213BCE59 wds:Q37302364-B7E612B7-EEE5-4C0C-BD08-05BECF2E33D6 wds:Q37302364-C4925590-7549-4B0C-BD62-450DF1C73504 wds:Q37302364-CD321331-A4CE-436B-A63F-870229B0BA7E wds:Q37302364-D60E3745-C3FD-454D-BE19-6E60EC324BA8 wds:Q37302364-D87B9252-0717-4EBB-B585-5F0F728FC3FE wds:Q37302364-D96F6ADE-44B7-4FD9-99F8-13C0DA6C8F8F wds:Q37302364-DD097579-B401-4751-A8C6-F0FF6AE7A61D wds:Q37302364-E8A7D9FF-3BBD-44F3-A7B0-B0CF7DDE538B wds:Q37302364-EA177BA6-8F8C-4565-9EA0-724815D6C4A3 wds:Q37302364-ECE3DA4A-AFC3-4BFA-B890-0B718E3E3EFC wds:Q37302364-ECF457EB-8FB4-4657-AD14-3FB1696844C1 wds:Q37302364-EE8960F8-5B98-4770-BC7F-F8AA3A8A3073 wds:Q37302364-F8655AE5-7475-4ACF-AD25-CF3A87574280 wds:Q37302364-F9D596F4-1A5D-4603-B245-3EFAA4C6013F
cites work	Insight and negative symptoms as predictors of functioning in a work setting in patients with schizophrenia The burden of schizophrenia on caregivers: a review Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorder II. Predictive value of psychosocial factors. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. EQ-5D: a measure of health status from the EuroQol Group What does the PANSS mean? SF-36 health survey update The positive and negative syndrome scale (PANSS) for schizophrenia Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation Pyramidical model of schizophrenia Relationship of cognition and psychopathology to functional impairment in schizophrenia The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome Development of an abbreviated schizophrenia quality of life scale using a new method. Quality of Life Benefits of Paid Work Activity in Schizophrenia Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia Detecting improvement in quality of life and symptomatology in schizophrenia Schizophrenia Quality of Life Scale: validation of the Japanese version. Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial Factor structure and external validity of the PANSS revisited A Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study. A longitudinal analysis of the impact of social and clinical characteristics on the costs of schizophrenia treatment. Integrated treatment of schizophrenia Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. Psychometric qualities of the French version of the Heinrichs quality of life rating scale Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function Condensed version of the Quality of Life Scale for schizophrenia for use in outcome studies. Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics Cognitive effects of olanzapine treatment in schizophrenia.
author name string	wds:Q37302364-3B3963B2-6978-4F71-858C-900C0DE5276D wds:Q37302364-66087A42-4CA2-42AF-AACF-97060DBA188C
author name string	Jaume Aguado Zhanglin Cui
rdfs:label	Empirically driven definitions of "good," "moderate," and "poor" levels of functioning in the treatment of schizophrenia (en)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software